Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.

What Was Tested

The paper reports a study of Human Growth Hormone and Metformin, published as a randomized controlled trial.

Adiponectin is a recently discovered adipocytokine that correlates negatively with body mass index and body fat.

Who Took Part

The study group was 14 men.

PubMed indexes the participants as middle-aged adults, men only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The men were allocated by chance, so the Human Growth Hormone group and the comparison group should start out alike.

As a double-blind Human Growth Hormone study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Human Growth Hormone group a baseline to be compared against.

Glucose disposal rate (GDR) was measured using the euglycemic hyperinsulinemic clamp technique, and body composition was measured by DEXA at 0 and 18 months.

What Was Measured

The subject headings attached to it are Adiponectin, Body Composition, Diabetes Mellitus, Type 2, Human Growth Hormone, Hypoglycemic Agents, Insulin Resistance and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Human Growth Hormone and Metformin in 14 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.